Q2 2025 PolyPid Ltd Earnings Call Transcript
Key Points
- PolyPid Ltd (PYPD) reported successful results from its SHIELD II Phase 3 trial, showing significant clinical benefits of D-PLEX100 in preventing surgical site infections.
- The trial demonstrated a 58% reduction in surgical site infections with D-PLEX100 compared to standard care, with a statistically significant p-value below 0.005.
- D-PLEX100 showed a 62% reduction in patients with severe wound infections, indicating less medical burden and improved patient outcomes.
- The company is on track with its regulatory submissions, planning a pre-NDA meeting with the FDA by the end of the year and NDA submission in early 2026.
- PolyPid Ltd (PYPD) has strengthened its balance sheet, extending its cash runway well into 2026 through a successful warrant exercise inducement transaction.
- PolyPid Ltd (PYPD) reported a net loss of $10 million for the second quarter of 2025, an increase from the $6.3 million loss in the same period of 2024.
- Research and development expenses increased to $6.2 million from $4.8 million in the same period of 2024, primarily due to activities related to the SHIELD II Phase 3 trial.
- General and administrative expenses rose to $2.5 million from $1.1 million in the same period of 2024, driven by non-cash expenses related to performance-based options.
- Marketing and development expenses increased to $0.7 million from $0.3 million in the same period of 2024.
- The company faces uncertainties and risks related to regulatory approvals and potential delays in the NDA submission process.
Greetings and welcome to PolyPid second quarter 2025 conference call. (Operator Instructions) As a reminder, this call is recorded. And I would now like to introduce your host for today's conference, Yehuda Leibler, from ARX Capital Markets. Mr. Leibler, you may begin.
Thank you all for participating in PolyPid's second quarter 2025 earnings conference call. Joining me on the call today will be Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid; Jonny Missulawin, PolyPid's Chief Financial Officer; and Ori Warshavsky, Chief Operating Officer, US of PolyPid.
Earlier today, PolyPid released its financial results for the three months ended June 30, 2025. A copy of the press release is available in the investors section on the company's website, available at www.polypid.com. I'd like to remind you that on this call, management will make forward-looking statements within the meaning of the Federal securities law.
For
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
